AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$AEHR

Erickson Gayn sold $5.2M of AEHR (indirect holdings)

Erickson Gayn (President and CEO) sold 40,000 indirectly-held shares of AEHR TEST SYSTEMS (AEHR) at an average of $130.84 ($130.79–$132.27, $5.23M total) across 2 trades on 2026-08-12.

Original reporting
SEC EDGAR · Erickson Gayn
Published Aug 13, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 10:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or unusual selling patterns, but this filing alone does not change AEHR’s operating outlook.

02

Market read

A $5.23M CEO sale is disclosed, but there is no new fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; the filing does not provide intent or linkage to company performance.

Relevance 6/10Novelty 3/10Timing: filed after-hours on 2026-08-13, covering sales on 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for AEHR, reported by CEO Erickson Gayn as an indirect holding sale.

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

AEHR CEO Erickson Gayn sold $5.23M of AEHR shares via open-market sales, reducing holdings to 157,723 shares.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

Form 4 shows sale size and pricing range, but provides no earnings, guidance, deal, or regulatory catalyst. Insider sales are common and often non-informational, though the absence of a stated 10b5-1 plan can add minor uncertainty.

Market effects

Sector

No clear sector read-through from a single insider sale without accompanying corporate or regulatory developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The CEO’s sale without a stated 10b5-1 plan could be interpreted as higher near-term risk tolerance or liquidity need, potentially weighing on sentiment.

Key entities

  • issuer
    AEHR

    AEHR Test Systems, the company whose shares were sold by its CEO.

  • insider
    Erickson Gayn

    President and CEO of AEHR, reporting open-market sales of shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AEHR insider trading history →

Related articles

$AEHRHighAI 9/10

Aehr Test Systems (AEHR) (Q1 2027) Earnings Call Highlights: Record Revenue, Raised

Aehr Test Systems (AEHR) reported record Q1 2027 revenue of $33M and raised annual guidance to $150M. CEO Gayn Erickson highlighted a potential large burn-in opportunity, estimating $35M-$70M in revenue per million units shipped. The company expects sequential growth in remaining quarters, with Q4 potentially the highest. Management confirmed they are not supply-constrained and can ship more than guided. Silicon carbide revenue was about $10M in fiscal 2026, with expectations for growth in 2027.

finance.yahoo.com
$AEHRHighAI 9/10

AEHR Stock Surges After Massive AI-Driven Earnings Beat

Aehr Test Systems (AEHR) stock rose 26.6% after reporting Q1 FY27 revenue of $33M, up 300% year-over-year and 75% quarter-over-quarter. Adjusted EPS was $0.28, beating estimates. The company raised FY27 revenue guidance to $150M, citing strong demand for AI and power semiconductor testing.

timothysykes.com
$AEHRHighAI 9/10

Aehr Stock Jumps 16% After Bookings Hit $46.7 Million

Aehr Test Systems (AEHR) shares rose 16.38% premarket after its Q1 revenue tripled to $33.0M, beating estimates. The company raised its full-year outlook to $150M, citing strong bookings and backlog growth. CEO Gayn Erickson highlighted a major AI customer opportunity. According to GuruFocus, there are 6 warning signs with AEHR.

finance.yahoo.com
$AEHRHighAI 8/10

Why is Aehr Test Systems stock surging today?

Aehr Test Systems (AEHR) stock surged 18.8% in pre-market trading after reporting record Q1 2027 revenue of $33.0M, up 200% YoY, and raising full-year revenue outlook to $150M. Non-GAAP net income was $9.4M, or $0.28 per share, exceeding analyst estimates. The company cited strong demand for AI semiconductor test solutions and a book-to-bill ratio of 1.4.

investing.com
$AEHRMed

Aehr stock jumps on beat and raise amid AI demand

Aehr Test Systems (AEHR) shares rose 15% after reporting Q1 revenue of $33M, up 200% YoY, and raising its FY2027 outlook to $150M. The company cited strong demand for its semiconductor testing systems used in AI chips. CEO Gayn Erickson noted a conservative approach to the revised target. Bookings were $46.7M with a book-to-bill ratio of 1.4.

tradingview.com